Brind.
  1. Rigel Pharmaceuticals' stock gain contrasts with the performance of the Zacks Medical sector.

High accrual ratio suggests lower profit growth for Rigel Pharmaceuticals as of August 13, 2025.

1 report, 1 independent Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

High accrual ratio suggests lower profit growth for Rigel Pharmaceuticals as of August 13, 2025.

Keep exploring

Coverage

Newest first; wire copies grouped
  • Simply Wall St.Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are Of Questionable Quality Explore Rigel Pharmaceuticals's Fair Values from the Community and select yours Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) s